Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha in High-Risk Patients, with Median 44 mg/dL LDL-C Achieved THOUSAND OAKS, Calif., March...
Hence then, the article about repatha cuts risk of first major cardiovascular events by 31 in high risk patients without known significant atherosclerosis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS )
Also on site :
- Peter Alexander is leaving NBC after years of being passed over for top anchor jobs: source
- London anti far-right march – latest: Police brace for unrest as thousands of protesters descend on capital
- The Japanese Concept a Psychologist Swears by To Find Purpose in Life